Percepta® Bronchial Genomic Classifier
Reducing unnecessary invasive procedures in lung cancer diagnosis

The Percepta Bronchial Genomic Classifier uses advanced genomic technology to improve lung cancer diagnosis for patients, reducing the need for invasive procedures that can follow when potentially cancerous lung nodules or lesions are found on CT scans. Lung cancer is the leading cause of cancer deaths in the United States, killing more than 154,000 Americans each year—more than the next three leading cancers combined.

Early detection is key to reducing lung cancer deaths and typically begins with identification of lung nodules on CT scans – either through screening or incidentally. Determining whether lung nodules identified on CT scans are cancerous is often difficult, however, which can lead to patients undergoing invasive, risky and expensive procedures that are often unnecessary. The need to improve lung cancer diagnosis has become especially important since 2015, when more than eight million Americans at high risk for lung cancer became eligible for annual low-dose CT screening through their insurance providers.
The Percepta classifier is a valuable tool that improves the diagnostic performance of bronchoscopy – a nonsurgical procedure that is frequently used to evaluate potentially cancerous lung nodules. The Percepta test is backed by strong clinical evidence — including clinical validation data published in The New England Journal of Medicine — demonstrating its accuracy in identifying patients who are at low and very low risk of cancer following inconclusive results from bronchoscopy. These patients may then be monitored with CT scans in lieu of undergoing further invasive diagnostic procedures.

The Percepta classifier uses novel “field of injury” technology, which detects genomic changes associated with lung cancer in the main airway of current and former smokers (who account for 90 percent of lung cancer cases). This enables the Percepta test to determine if a nodule located deep in the lung is likely cancerous – without needing to access the nodule directly.

Reducing unnecessary invasive procedures in lung cancer diagnosis
Advanced genomic technology backed by strong clinical evidence.